{
    "nct_id": "NCT05828589",
    "official_title": "A Phase 1/1b Open-Label Dose-Escalation Study of Bcl-2 Inhibitor BGB-21447 in Patients With Mature B-Cell Malignancies",
    "inclusion_criteria": "Healthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "1. Prior malignancy (other than the disease under study) within the past 2 years, except for curatively treated basal or squamous skin cancer, superficial bladder cancer, carcinoma in situ of the cervix or breast, or localized Gleason score â‰¤ 6 prostate cancer\n2. Known central nervous system involvement by lymphoma/leukemia\n3. Prior autologous stem cell transplant < 3 months before the first dose of study drug. Or prior chimeric antigen receptor T-cell (CAR-T) therapy < 3 months before the first dose of study drug\n4. Prior allogeneic stem cell transplant.\n5. Major surgery < 4 weeks before the first dose of study treatment\n\nNOTE: Other protocol-defined Inclusion/Exclusion criteria may apply.",
    "miscellaneous_criteria": "Inclusion Criteria\n\n1. Confirmed diagnosis (per World Health Organization [WHO] guidelines, unless otherwise noted) of one of the following:\n\n   Cohort A1 and Cohort A2:\n   1. R/R DLBCL\n   2. R/R FL\n   3. R/R MZL\n   4. Transformed B-cell NHL\n   5. Richter's transformation to DLBCL\n2. Measurable disease by computed tomography/magnetic resonance imaging."
}